

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

**In re: CHANTIX (VARENICLINE)
MARKETING, SALES PRACTICES,
AND PRODUCTS LIABILITY
LITIGATION II**

22-MD-3050 (KPF)
22-MC-3050 (KPF)

**DECLARATION OF MARIE A. CHRISTIE REGARDING
DISSEMINATION OF NOTICE AND REPORT ON OPT OUT REQUESTS
AND OBJECTIONS RECEIVED TO DATE**

I, Marie A. Christie, pursuant to 28 U.S.C. § 1746, declare as follows:

1. I am a Senior Project Manager of A.B. Data, Ltd.’s Class Action Administration Company (“A.B. Data”), whose corporate office is located in Milwaukee, Wisconsin. My business address is 5080 PGA Boulevard, Suite 209, Palm Beach Gardens, FL 33418, and my telephone number is 561-308-9661. I have personal knowledge of the facts set forth herein and, if called as a witness, could and would testify competently thereto.

2. Pursuant to the Class Action Settlement Agreement, dated May 26, 2026, (the “Settlement Agreement”) and the Court’s Preliminary Approval Order (ECF No. 133), A.B. Data was responsible for effectuating notice pursuant to the notice plan approved by the Court (the “Notice Plan”).

DIRECT MAIL NOTICE TO TPPS

3. On July 13, 2026, pursuant to the Court-approved Notice Plan, A.B. Data mailed the postcard notice (the “Postcard Notice”) *via* USPS First-Class Mail to 42,167 entities in A.B. Data’s Third-Party Payor (“TPP”) Database. These entities include insurance companies, health maintenance organizations, and self-insured entities, as well as pharmacy benefits managers

(“PBMs”), third-party administrators (“TPAs”), and other entities that represent potential TPP Settlement Class Members. A copy of the Postcard Notice is attached hereto as **Exhibit A**. As of September 24, 2026, 1,099 Notices have been returned by the USPS as undeliverable as addressed, without a forwarding address. A.B. Data performed skip tracing for addresses for each of the 1,099 undeliverable Notices. The skip tracing produced 1,014 updated addresses. A.B. Data re-mailed 1,014 Postcard Notices to the updated addresses obtained from the skip traces.

4. In addition, on July 13, 2026, A.B. Data sent 2,027 emails to emails to TPPs and their representatives where email addresses were available and 1,530 were valid and successfully delivered. A.B. Data did not make further attempts to locate a current email address to re-notice these entities, as they were also included in the Postcard Notice mailing.

DIGITAL MEDIA

5. Beginning on July 13, 2026, A.B. Data caused internet banner ads and social media newsfeed ads to appear on various websites and social media platforms for 30 days. The planned total was 15,000,000 impressions, and we overdelivered by 2,069,744 impressions. Over 17 million impressions were delivered to potential Consumer and TPP Settlement Class Members. When clicked, the banners directed potential Settlement Class Members to the case website (ChantixSettlement.com) (the “Settlement Website”). The following digital and social media networks were included in the campaign:

- a. GDN/YouTube: 16,266,480 impressions
- b. Search: 41,637 impressions
- c. Facebook/Instagram: 761,627 impressions

6. To specifically further reach TPP Settlement Class Members, A.B. Data also caused digital banner ads to appear on the following websites: ThinkAdvisor.com; BenefitNews.com; and SHRM.org. These websites were selected for their ability to provide impressions to insurance

agents, brokers, human resource management personnel, and related TPP professionals. These TPP-directed placements delivered 426,546 impressions, in addition to those delivered by the campaign described in paragraph 4, above.

7. A sampling of the Consumer and TPP digital banner ads is attached hereto as **Exhibit B**.

CAFA NOTICE

8. On July 13, 2026, pursuant to the Court-approved Notice Plan, A.B. Data caused fifty-two (52) CAFA Notices to be sent via the United States Postal Service (“USPS”) Priority Mail or Certified Mail (where Priority Mail was not available) and three (3) via e-mail as requested by certain States, to the United States Attorney General, the Attorneys General of each of the 50 States and the District of Columbia, and the Attorneys General of the recognized U.S. Territories. There were no CAFA Notices returned as undelivered.

EARNED MEDIA

9. In accordance with the Notice Plan, A.B. Data caused the Notice, formatted as a news release, to be disseminated via *PR Newswire* on July 13, 2026. This Notice was distributed via *PR Newswire* to the news desks of over 10,000 newsrooms across the United States. A copy of the news release is attached hereto as **Exhibit C**.

TELEPHONE HELPLINE AND WEBSITE

10. On July 13, 2026, A.B. Data established the Settlement Website (ChantixSettlement.com). The Settlement Website includes information regarding the Action, including the objection, exclusion, and claim filing deadlines, the date, time, and location for the Court’s Final Approval Hearing, and frequently asked questions about the Settlement. Copies of

the Long-Form Consumer and TPP Notices (attached as **Exhibits D** and **E**), Motion for Preliminary Approval and related declarations, Preliminary Approval Order and Notice Date Extension Order, Settlement Agreement, Motion for Attorneys' Fees and related declarations, and other relevant documents are posted on the Settlement Website and are available for downloading. In addition, the Settlement Website allows Consumer and TPP Settlement Class Members to submit their claim forms online. The website is accessible 24 hours a day, 7 days a week. Through August 31, 2026, the website had 131,167 unique hits/visitors.

11. A.B. Data also continues to maintain a case-specific toll-free number, 877-354-3912, with an IVR system and live operators, to answer questions about the Settlement. The automated attendant answers calls and presents callers with a series of choices to answer basic questions. If callers need further help, they can ask to be transferred to a live operator during business hours. Through August 31, 2026, the line received 230 phone calls.

REPORT ON OPT-OUT REQUESTS

12. The Notices informed Settlement Class Members that if they wish to request exclusion from the Settlement Class, they must submit a written request to the Settlement Administrator postmarked if sent by mail, or submitted through the Settlement Website to include their full name and current address, a statement that they purchased Chantix in the United States and its territories between September 29, 2015 through September 17, 2021, their signature, the name and number of this case, and a statement that they wish to be excluded, no later than 11:59 P.M. on September 14, 2026. As of the date of this Declaration, A.B. Data has received two (2) requests for exclusion.

REPORT ON OBJECTIONS

13. The Notices informed Settlement Class Members that the deadline to object is

September 14, 2026. Settlement Class Members who wish to object were instructed to give reasons why they think the Court should not approve the Settlement, Plan of Allocation, and/or Motion for Attorneys' Fees, Expenses, and Service Awards, in addition to the following: the Settlement Class Member must file with the Court a letter or brief stating that they object to the Settlement in *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.) and identify all reasons for the objections (including citations and supporting evidence) and attach any materials relied on for the objection(s); the letter or brief must also include their name, their address, the basis upon which they claim to be a Settlement Class Member, the name and contact information of any and all attorneys representing, advising, or in any way assisting them in connection with the objection, and their signature. The Settlement Class Members were further instructed that if they, or an attorney assisting with the objection, have ever objected to any class action settlement where they or the objecting attorney has asked for or received payment in exchange for dismissal of the objection (or any related appeal) without modification to the settlement, they must include a statement in the objection identifying each such case by full case caption; the objections must be mailed or a copy of the letter or brief delivered to Class Counsel and Pfizer's Counsel. Although the Notices did not direct Settlement Class Members to submit objections to A.B. Data, for completeness I report that, as of the date of this Declaration, A.B. Data has not received any objections.

REPORT ON CLAIMS

14. The Notices and Claim Forms advised Settlement Class Members that to be eligible to receive a payment if the Court approves the Settlement, they must complete and submit a valid Claim Form by September 14, 2026. As of the date of this Declaration, A.B. Data has received 17,885 TPP claims and 3,581,486 Consumer claims. None of the claims received have yet been

validated, and the figures reported above are necessarily preliminary. In my experience administering class action settlements, Claim Forms submitted by mail continue to be received after the deadline. In addition, A.B. Data has not yet completed its review of the Claim Forms received: each must be reviewed for completeness, deduplicated against other submissions and against A.B. Data's records, and screened for indicia of fraudulent or otherwise ineligible submissions, and claimants whose Claim Forms contain curable deficiencies are afforded an opportunity to cure. Therefore, these numbers will change as claims continue to be received, reviewed, and validated.

CONCLUSION

15. The direct notice campaign successfully delivered Direct Notice to 43,697 individuals which represents a 98.9% delivery rate. Additionally, the media notice campaign delivered over 17 million impressions to potential Consumer and TPP Settlement Class Members, while the earned media and news coverage concerning the Settlement provided additional awareness.

16. While precise reach is not calculable given the unknown Settlement Class size, it remains my professional opinion that the Notice Plan implemented in this Settlement provided full and proper notice to members of the Settlement Class before the applicable response deadlines, and that the Notice Plan is the best notice practicable under the circumstances, fully comporting with due process and Fed. R. Civ. P. 23.

I declare under penalty of perjury that the foregoing is true and correct.

Executed in Stuart, Florida this 28th day of September, 2026.



Marie A. Christie

EXHIBIT A

LEGAL NOTICE

**If You are a Third-Party Payor who Paid
Any Amount of Money for Retail Purchases
of Chantix in the United States and Its
Territories from September 29, 2015
through September 17, 2021,**

***You May Be Entitled to a Payment from a Class
Action Settlement.***

A Settlement has been reached in a putative class action lawsuit claiming that Defendant Pfizer, Inc. (“Pfizer”) manufactured and sold its branded drug Chantix, which Plaintiffs alleged contained an undisclosed nitrosamine. Pfizer believes it did nothing wrong and denies violating any law but has agreed to the Settlement to avoid the uncertainties and expenses associated with continuing the case.

The Court has not determined who is right. Rather, the Parties have agreed to settle the lawsuit to avoid the uncertainties and expenses associated with ongoing litigation.

The Court authorized this notice to be provided to you by email, where available, or United States mail in certain limited circumstances.

Chantix Settlement
c/o A.B. Data, Ltd.
P.O. Box 173137
Milwaukee, WI 53217

Postmaster: Please DO NOT Cover Up Barcode

<<Barcode>>

<<Claim ID>>

<<Mailing Address>>

Who's included in the Settlement? The Settlement Class includes all third-party payors ("TPPs") and individuals who paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. Detailed information regarding the Settlement Class and how to determine your eligibility is available on the Settlement Website, www.ChantixSettlement.com.

What are the Settlement Benefits? Pfizer will pay \$44,000,000.00 to the Settlement Class Members. Settlement Class Member payments, the cost to notice and administer the Settlement, attorneys' fees, litigation costs, and awards to the class representatives will all come out of this Fund. The total payment to consumers will be on a *pro rata* basis based on the amount paid by each consumer Settlement Class Member and will be capped at 20% of the Available Settlement Fund, and each consumer's claim will not exceed the total amount paid for Chantix. After payment of the consumer claims, the remainder of the Fund shall be distributed to the TPP Settlement Class Members (including assignees) on a *pro rata* basis, according to the total amount of each TPP's qualifying and documented payments. Complete details can be found at www.ChantixSettlement.com.

What are my rights and options?

Submit a Claim: To receive a Settlement payment, you must submit a Claim Form. You can submit your Claim Form online at the Settlement Website or download a paper TPP Claim Form to mail in. Claim Forms must include supporting documentation. Settlement Class Members are limited to one claim per Settlement Class Member. Related companies, such as corporate subsidiaries or affiliates, may file claims either separately or combined. A TPP Settlement Class Member or an authorized agent can complete the Claim Form. If both a Settlement Class Member and its authorized agent submit a Claim Form, the Settlement Administrator will only consider the Settlement Class Member's Claim Form. The Settlement Administrator may request supporting documentation. The claim may be rejected if any requested documentation is not provided in a timely manner. However, no more than one claim may be submitted for the same payments. Your Claim Form must be submitted online or postmarked by **September 14, 2026**.

Do Nothing: If you do nothing, you will remain a part of the Settlement Class and Settlement. You will receive no payment under the Settlement, and you will give up your rights to sue Pfizer about the issues in this case.

Opt Out: Excluding yourself is the only way to keep your right to sue Pfizer over the claims in this case. You won't be bound by the Settlement, but you also won't receive any payment from it, if one is awarded. To opt-out, you must submit an exclusion request to the Settlement Administrator, postmarked no later than **September 14, 2026**.

Object: If you do not like any part of the Settlement, you can object by writing to the Court. You cannot submit both an exclusion request and objection. To object, you must remain a Settlement Class Member. If the Court rejects your objection and enters the Final Judgment, you will give up your rights to sue Pfizer about the issues in this case. If you also wish to receive payment, you must submit a Claim Form. Your objection must be postmarked no later than **September 14, 2026**.

Complete details about your rights, including detailed requirements to submit a Claim Form, exclude yourself/opt-out, and object to the Settlement, are available on the Settlement Website, www.ChantixSettlement.com.

Final Approval Hearing: The hearing to consider the fairness of the Settlement is scheduled for **October 13, 2026, at 3:00 p.m.** Please note that the fairness hearing date is subject to change without further notice.

Do I have a lawyer in this case? Yes, if you do not exclude yourself by opting out. The Court has appointed Ruben Honik and David J. Stanoch of Honik LLC, Charles E. Schaffer of Levin Sedran & Berman LLP, and Joseph P. Guglielmo of Scott+Scott Attorneys at Law LLP to be the attorneys representing the Settlement Class. Class Counsel will petition for attorneys' fees and costs that may be paid out of the Settlement Fund in an amount to be determined by the Court. The fee petition will seek no more than one-third of the Settlement Fund, plus reimbursement of their costs and expenses.

This Notice is only a summary. For more information: **Call 1-877-354-3912 or visit www.ChantixSettlement.com**

EXHIBIT B

If you are a patient
who paid any
amount of money for
retail purchases of
CHANTIX[®]
(Varenicline)

*You may be entitled to
a payment from a
Class Action
Settlement*



not actual pill

**Click Here to
File a Claim:**

ChantixSettlement.com

If you are a Third-Party
Payor who paid any
amount of money for
retail purchases of
CHANTIX[®]
(Varenicline)

*You may be entitled
to a payment from a
Class Action
Settlement*



not actual pill

**Click Here to
File a Claim:**

ChantixSettlement.com

EXHIBIT C

Honik LLC, Levin Sedran & Berman LLP, and Scott+Scott Attorneys at Law LLP Announce A \$44 Million Settlement in an Economic Loss Class Action for Third-Party Payors or Individuals Who Paid Any Amount of Money for Retail Purchases of Chantix From September 29, 2015 through September 17, 2021

NEWS PROVIDED BY

Honik LLC, Levin Sedran & Berman LLP and Scott+Scott Attorneys at Law LLP
Jul 13, 2026, 17:00 ET

PHILADELPHIA, July 13, 2026 /PRNewswire/ --

United States District Court for the Southern District of New York

In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig. (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.)

If You are a Third-Party Payor or Individual who Paid Any Amount of Money for Retail Purchases of Chantix in the United States and Its Territories from September 29, 2015 through September 17, 2021, You May Be Entitled to a Payment from a Class Action Settlement.

A Settlement has been reached in a putative class action lawsuit claiming that Defendant Pfizer, Inc. ("Pfizer") manufactured and sold its branded drug Chantix, which Plaintiffs alleged contained an undisclosed nitrosamine. Pfizer believes it did nothing wrong and denies violating any law but has agreed to the Settlement to avoid the uncertainties and expenses associated with continuing the case.

The Court has not determined who is right. Rather, the Parties have agreed to settle the lawsuit to avoid the uncertainties and expenses associated with ongoing litigation.

The Court authorized this notice to be provided to you by email, where available, or United States mail in certain limited circumstances.

Who's Included in the Settlement?

The Settlement Class includes all third-party payors ("TPPs") and individuals who paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021.

Detailed information regarding the Settlement Class and how to determine your eligibility is available on the Settlement Website, www.ChantixSettlement.com.

The Settlement Benefits

Pfizer will pay \$44,000,000.00 to the Settlement Class Members. Settlement Class Member payments, the cost to notice and administer the Settlement, attorneys' fees, litigation costs, and awards to the class representatives will all come out of this Fund. The total payment to consumers will be on a *pro rata* basis based on the amount paid by each consumer Settlement Class Member and will be capped at 20% of the Available Settlement Fund, and each consumer's claim will not exceed the total amount paid for Chantix. After payment of the consumer claims, the remainder of the Fund shall be distributed to the TPP Settlement Class Members (including assignees) on a *pro rata* basis, according to the total amount of each TPP's qualifying and documented payments.

Complete details can be found at www.ChantixSettlement.com.

What are my rights and Options?

Submit a Claim: To receive a Settlement Payment, you must submit a Claim Form. You can submit your Claim Form online at the Settlement Website or download a paper Claim Form to mail in. Claim Forms must include supporting documentation. Settlement Class Members are limited to one claim per Settlement Class Member. Related companies, such as corporate subsidiaries or affiliates, may file claims either separately or combined. A TPP Settlement Class Member or an authorized agent can complete the Claim Form. If both a Settlement Class Member and its authorized agent submit a Claim Form, the Settlement Administrator will only consider the Settlement Class Member's Claim Form. The Settlement Administrator may request supporting documentation. The claim may be rejected if any requested documentation is not provided in a timely manner. However, no more than one claim may be submitted for the same payments. Your Claim Form must be submitted online or postmarked by **September 14, 2026**.

Do Nothing: If you do nothing, you will remain a part of the Settlement Class and Settlement. You will receive no payment under the Settlement, and you will give up your rights to sue Pfizer about the issues in this case.

Opt-Out: Excluding yourself is the only way to keep your right to sue Pfizer over the claims in this case. You won't be bound by the Settlement, but you also won't receive any payment from it, if one is awarded. To opt-out, you must submit an exclusion request to the Settlement Administrator, postmarked no later than **September 14, 2026**.

Object: If you do not like any part of the Settlement, you can object by writing to the Court. You cannot submit both an exclusion request and objection. To object, you must remain a Settlement Class Member. If the Court rejects your objection and enters the Final Judgment, you will give up your rights to sue Pfizer about the issues in this case. If you also wish to receive payment, you must submit a Claim Form. Your objection must be postmarked no later than **September 14, 2026**.

Complete details about your rights, including detailed requirements to submit a Claim Form, exclude yourself/opt-out, and object to the Settlement, are available on the Settlement Website, www.ChantixSettlement.com.

Final Approval Hearing: The hearing to consider the fairness of the Settlement is scheduled for **October 13, 2026 at 3 P.M. EST**. Please note that the fairness hearing date is subject to change without further notice.

Do I have a lawyer in this case? Yes, if you do not exclude yourself by opting out. The Court has appointed Ruben Honik and David J. Stanoch of Honik LLC, Charles E. Schaffer of Levin Sedran & Berman LLP, and Joseph P. Guglielmo of Scott+Scott Attorneys at Law LLP to be the attorneys representing the Settlement Class. Class Counsel will petition for attorneys' fees and costs that may be paid out of the Settlement Fund in an amount to be determined by the Court. The fee petition will seek no more than one-third of the Settlement Fund, plus reimbursement of their costs and expenses.

This Press Release is only a summary. For more information, including the defined meanings of capitalized terms herein, visit the Settlement Website:

www.ChantixSettlement.com

SOURCE Honik LLC, Levin Sedran & Berman LLP and Scott+Scott Attorneys at Law LLP

EXHIBIT D

UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK
In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig. (No. II) 22-MD-3050
 (KPF), 22-MC-3050 (S.D.N.Y.)

If You Paid Any Amount of Money for Retail Purchases of Chantix in the United States and Its Territories from September 29, 2015 through September 17, 2021, You May Be Entitled to a Payment from a Class Action Settlement.

A court authorized this notice. You are not being sued. This is not a solicitation from a lawyer.

- A Settlement has been reached in a putative class action lawsuit claiming that Defendant Pfizer, Inc. (“Pfizer”) manufactured and sold its branded drug Chantix, which Plaintiffs alleged contained an undisclosed nitrosamine. Pfizer believes it did nothing wrong and denies violating any law but has agreed to the Settlement to avoid the uncertainties and expenses associated with continuing the case.
- You are included if you paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. Persons included in the Settlement will be eligible to receive a *pro rata* portion of up to twenty (20) percent of the Settlement Fund, which will be based on the amount you paid for Chantix.
- Read this notice carefully. Your legal rights are affected whether you act, or do not act.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A CLAIM FORM BY SEPTEMBER 14, 2026	This is the only way to receive a payment.
EXCLUDE YOURSELF BY SEPTEMBER 14, 2026	You will receive no benefits, but you will retain any rights you currently have to sue Pfizer about the claims in this case.
OBJECT BY SEPTEMBER 14, 2026	Write to the Court explaining why you do not like the Settlement.
GO TO THE HEARING ON OCTOBER 13, 2026	Ask to speak in Court about your opinion of the Settlement.
DO NOTHING	You will not receive a share of the Settlement benefits and will give up your rights to sue Pfizer about the claims in the case.

These rights and options—**and the deadlines to exercise them**—are explained in this Notice.

BASIC INFORMATION

1. Why was this Notice issued?

A Court authorized this notice because you have a right to know about a proposed Settlement of this putative class action lawsuit and about all of your options, before the Court decides whether to give final approval to the Settlement. This Notice explains the lawsuit, the Settlement, and your legal rights.

The Honorable Katherine Polk Failla, of the U.S. District Court for the Southern District of New York, is overseeing this case. The case is called *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.). The people who sued are called the Plaintiffs. The Defendant is Pfizer.

2. What is a class action?

In a putative class action, one or more people called plaintiffs or class representatives (in this case, Juan Abreu, Teresa Baptiste, Timothy Bleeker, Harold Bradley, Sharon Carroll, Karen Duff, Albert Edwards, Tara Evans, Lillian Forrest, Kimberly Hill, Valerie Hogue, Douglas Houghton, James Jacobson, Tammy LaMotte, Kathleen Lima, Deborah Seeley, Daniel Spence, Hazel Taylor, Carita Thompson, Daphne Walter, and Shannon Webb a/k/a Shannon Alicea) (the “Consumer Plaintiffs”) and Plaintiffs County of Monmouth, MSP Recovery Claims Series 44, LLC, MSP Recovery Claims, Series LLC, and Ohio Carpenters’ Health Fund (the “TPP Plaintiffs”)) sue on behalf of a group or a “class” of people who have similar claims. If the court determines the case can proceed as a class action, the court resolves the issues for all class members, except for those who exclude themselves from the class.

3. What is this lawsuit about?

Plaintiffs alleged that Pfizer failed to comply with current good manufacturing practices, which resulted in Chantix becoming contaminated with a nitrosamine and asserted claims for: (1) breach of express warranties; (2) breach of implied warranties; (3) violation of the Magnuson-Moss Warranty Act, 15 U.S.C. § 2301 *et seq.*; (4) fraud (affirmative misrepresentation, omission, and concealment); (5) negligent misrepresentation and omission; (6) violation of state consumer protection laws; (7) negligence; (8) negligence per se; and (9) unjust enrichment. The Court issued prior orders that limited the claims to Plaintiffs’ consumer protection claims and certain unjust enrichment and negligent misrepresentation claims to proceed based on the “cGMP Misstatement, *i.e.*, that Pfizer misrepresented its adherence to current Good Manufacturing practices in its manufacturing of Chantix.” Pfizer believes it did nothing wrong and denies violating any law. The Court has not determined who is right. Rather, the Parties have agreed to settle the lawsuit to avoid the uncertainties and expenses associated with ongoing litigation.

4. Why is there a Settlement?

The Court has not decided whether the Plaintiffs or Pfizer should win this case. Instead, both sides agreed to a Settlement. That way, they avoid the uncertainties and expenses associated with ongoing litigation, and Settlement Class Members are guaranteed to receive compensation, and sooner rather than, if at all, after the completion of a trial.

WHO'S INCLUDED IN THE SETTLEMENT?

5. How do I know if I am in the Settlement Class?

The Court decided that everyone who fits the following description is a member of the **Settlement Class**:

All individuals and third-party payors who paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021.

The following groups have been excluded from the Settlement Class in this case:

- a. Pfizer and its officers, directors, managers, employees, subsidiaries, and affiliates;
- b. Government agencies or governmental actors, including, without limitation, any state Attorney General office, and
- c. Any entity that previously opted out of the Settlement Class in this Action.

THE SETTLEMENT BENEFITS

6. What does the Settlement provide?

In consideration of the full and complete release of all Released Claims against Pfizer, and the dismissal of the lawsuit with prejudice, Pfizer agrees to provide the following consideration to the Settlement Class: Pfizer will pay \$44,000,000.00.

The net Settlement Fund available for distribution to the Settlement Class, after deduction of any attorneys' fees, litigation expenses, settlement administration and notice expenses, and class representative service awards that may be ordered by the Court, shall be first allocated between the Consumer Settlement Class up to a maximum of 20% of the Available Settlement Fund, with the remainder allocated to third-party payors (described in a separate notice to the Third Party Payor Settlement Class); allocation to Consumer Settlement Class Members will be as follows:

For Consumers: After a determination of the total fund to be allocated to Consumers, each Consumer class member who submits an eligible claim will receive a *pro-rata* share of the funds based on dollars paid as documented in claim forms and supporting documents submitted, and each consumer's claim will not exceed the total amount paid for Chantix.

A detailed description of the Settlement benefits can be found in the Settlement Agreement, a copy of which is accessible on the Settlement Website by clicking [here](#).

7. How will my payment be determined?

To receive a *pro rata* share of the Settlement, which will be based on the amount you paid for Chantix, you must submit a timely and complete Claim Form no later than **September 14, 2026**. You can file a claim by clicking [here](#). Claim Forms must be submitted online by **11:59 p.m. EST on September 14, 2026** or postmarked and mailed by **September 14, 2026**.

You can contact Class Counsel at Ruben Honik, Honik Law, 1515 Market Street, Suite 1100, Philadelphia, PA, 19102 to inquire as to the number of claims and/or requests for exclusion that have been received to date.

8. When will I get my payment?

The hearing to consider the fairness of the Settlement is scheduled for **October 13, 2026 at 3:00 p.m.** Please note that the fairness hearing date is subject to change without further notice. If the Court approves the Settlement, there may be appeals. It is always uncertain when appeals will be resolved, and even if no appeals are filed, it also takes time for the Settlement Administrator to process all claims and make payments. Please be patient.

HOW TO GET BENEFITS

9. How do I get a payment?

If you are a Settlement Class Member and you want to get a payment, you **must** complete and submit a Claim Form by **September 14, 2026**. Claim Forms can be found and submitted by clicking [here](#), or by printing and mailing a paper Claim Form, copies of which are available for download [here](#).

We also encourage you to submit your claim online. Not only is it easier and more secure, but it is completely free and takes only minutes.

REMAINING IN THE SETTLEMENT

10. What am I giving up if I stay in the Settlement Class?

If the Settlement becomes final, you will give up your right to sue Pfizer and other Released Parties for the claims being resolved by this Settlement. The specific claims you are giving up against Pfizer are described in the Settlement Agreement. You will be “releasing” Pfizer and certain of its subsidiaries, affiliates, employees, and representatives as described in Section 3 of the Settlement Agreement. Unless you exclude yourself (*see* Question 13), you are “releasing” the claims, regardless of whether you claim your payment or not. The Settlement Agreement is available through the “Court Documents” link on the Settlement Website.

The Settlement Agreement describes the released claims with specific descriptions, so read it carefully. If you have any questions, you can talk to the lawyers listed in Question 11 for free or you can, of course, talk to your own lawyer if you have questions about what this means.

THE LAWYERS REPRESENTING YOU

11. Do I have a lawyer in the case?

Yes, if you do not exclude yourself from the Settlement Class by opting out. The Court has appointed Ruben Honik and David J. Stanoch of Honik LLC, Charles E. Schaffer of Levin Sedran & Berman LLP, and Joseph Guglielmo of Scott+Scott Attorneys at Law LLP to be the attorneys representing the Settlement Class. They are called “Class Counsel.” They believe, after conducting an extensive investigation, that the Settlement Agreement is fair, reasonable, and in the best interests of the Settlement Class. You will not be charged for these lawyers. If you want to be represented by your own lawyer in this case, you may hire one at your expense.

12. How will the lawyers be paid?

Class Counsel will petition for attorneys’ fees and costs that may be paid out of the Settlement Fund in an amount to be determined by the Court. The fee petition will seek no more than one-third of the Settlement Fund, plus reimbursement of their costs and expenses. Under the Settlement Agreement, any amount awarded to Class Counsel will be paid out of the Settlement Fund.

Subject to approval by the Court, Plaintiff intends to seek service awards for the Class Representatives from the Settlement Fund in the amount of \$15,000 each for TPP Plaintiffs and \$5,000 each for Consumer Plaintiffs in recognition for their services in helping to bring and resolve this case.

EXCLUDING YOURSELF FROM THE SETTLEMENT

13. How do I get out of the Settlement?

To exclude yourself from the Settlement, you must submit a request for exclusion by **11:59 P.M. EST on September 14, 2026**. Requests for exclusion may be submitted either on the Settlement Website (via the online form accessible [here](#)) or by mailing or otherwise deliver a letter (or request for exclusion) stating that you want to be excluded from the *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.) Settlement. Your letter or request for exclusion must also include your full name and current address, a statement that you purchased Chantix in the United States and its territories between September 29, 2015 through September 17, 2021, your signature, the name and number of this case, and a statement that you wish to be excluded. If you choose to submit a request for exclusion by mail, you must mail or deliver your exclusion request, postmarked no later than **September 14, 2026**, to the following address:

Chantix Settlement
c/o A.B. Data, Ltd.
P.O. Box 173137
Milwaukee, WI 53217

Any purported group, “mass,” or “class-wide” opt-outs shall not be permitted and shall be construed as being submitted only on behalf of the person who actually submitted the request for exclusion or objection. A request for exclusion must be submitted by each Settlement Class Member on an individual basis, and any request for exclusion by a purported authorized agent or representative of a Settlement Class Member must be signed by the Settlement Class Member and include proof of the representative’s legal authority and authorization to act and object to or request exclusion on behalf of each Settlement Class Member for which the representative requests exclusion.

14. If I do not exclude myself, can I sue Pfizer for the same thing later?

No. Unless you exclude yourself, you give up any right to sue Pfizer for the claims being resolved by this Settlement.

15. If I exclude myself, can I get anything from this Settlement?

No. If you exclude yourself, you will not receive any payment from the Settlement Fund.

OBJECTING TO THE SETTLEMENT

16. How do I object to the Settlement?

If you are a Settlement Class Member, you can object to the Settlement if you do not like any part of it. The deadline to object is **September 14, 2026**. You can give reasons why you think the Court should not approve it. The Court will consider your views. To object, you must file with the Court a letter or brief stating that you object to the Settlement in *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.) and identify all your reasons for your objections (including citations and supporting evidence) and attach any materials you rely on for your objections. Your letter or brief must also include your name, your address, the basis upon which you claim to be a Settlement Class Member, the name and contact information of any and all attorneys representing, advising, or in any way assisting you in connection with your objection, and your signature. If you, or an attorney assisting you with your objection, have ever objected to any class action settlement where you or the objecting attorney has asked for or received payment in exchange for dismissal of the objection (or any related appeal) without modification to the settlement, you must include a statement in your objection identifying each such case by full case caption. You must also mail or deliver a copy of your letter or brief to Class Counsel and Pfizer’s Counsel listed below.

Objections must be filed via the Court's electronic filing system, and if not filed via the Court's electronic system, must be mailed, postmarked by **September 14, 2026**, to the Court at the following address:

Clerk of the Court
United States District Court
Southern District of New York
Thurgood Marshall
United States Courthouse
40 Foley Square
New York, NY 10007

If you want to appear and speak at the Final Approval Hearing to object to the Settlement, with or without a lawyer (explained below in Question 20), you must say so in your letter or brief. File the objection with the Court (or mail the objection to the Court) and mail a copy of the objection to Class Counsel and Pfizer's Counsel, at the addresses below, postmarked no later than **September 14, 2026**.

Class Counsel	Pfizer's Counsel
Ruben Honik Honik Law 1515 Market Street Suite 1100 Philadelphia, PA 19102	Loren H. Brown DLA Piper LLP 1251 Avenue of the Americas, 27th Floor New York, NY 10020

17. What's the difference between objecting and excluding myself from the Settlement?

Objecting simply means telling the Court that you do not like something about the Settlement. You can only object if you stay in the Settlement Class. Excluding yourself from the Settlement Class is telling the Court that you do not want to be part of the Settlement Class. If you exclude yourself, you have no basis to object because the case no longer affects you.

THE COURT'S FINAL APPROVAL HEARING

18. When and where will the Court decide whether to approve the Settlement?

The Court will hold the Final Approval Hearing on **October 13, 2026 at 3:00 p.m.** in Courtroom 618 of the United States District Court for the Southern District of New York, Thurgood Marshall United States Courthouse, 40 Foley Square, New York, NY 10007. The purpose of the hearing will be for the Court to determine whether to approve the Settlement as fair, reasonable, adequate, and in the best interests of the Settlement Class; consider Class Counsel's request for attorneys' fees and expenses; and consider the request for service

awards to the Class Representatives. At that hearing, the Court will be available to hear any objections and arguments concerning the fairness of the Settlement.

The hearing may be postponed to a different date or time without notice, so it is a good idea to check for updates by visiting the Settlement Website at www.ChantixSettlement.com or calling 1-877-354-3912. If, however, you timely objected to the Settlement and advised the Court that you intend to appear and speak at the Final Approval Hearing, you will receive notice of any change in the date of the Final Approval Hearing.

19. Do I have to come to the hearing?

No. Class Counsel will answer any questions the Court may have. But, you are welcome to come at your own expense. If you send an objection or comment, you do not have to come to Court to talk about it. As long as you filed and mailed your written objection on time, the Court will consider it. You may also pay another lawyer to attend, but it's not required.

20. May I speak at the hearing?

Yes. You may ask the Court for permission to speak at the Final Approval Hearing. To do so, you must include in your letter or brief objecting to the Settlement a statement saying that it is your "Notice of Intent to Appear in *In re Chantix (Varenicline) Mktg., Sales Prac. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.)." It must include your name, address, telephone number and signature, as well as the name and address of your lawyer, if one is appearing for you. Your objection and notice of intent to appear must be filed with the Court, postmarked no later than **September 14, 2026**, and sent to the addresses listed in Question 16.

GETTING MORE INFORMATION

21. Where do I get more information?

This Notice summarizes the Settlement. More details are in the Settlement Agreement. You can get a copy of the Settlement Agreement at www.ChantixSettlement.com. You may also write with questions to Chantix Settlement, c/o A.B. Data, Ltd., P.O. Box 173137, Milwaukee, WI 53217. You can call the Settlement Administrator at 1-877-354-3912 or Class Counsel at 212-223-6444, if you have any questions. Before doing so, however, please read this full Notice carefully. You may also find additional information elsewhere on the Settlement Website.

EXHIBIT E

UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK
In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig. (No. II) 22-MD-3050
 (KPF), 22-MC-3050 (S.D.N.Y.)

If You Are a Third Party Payor Who Paid Any Amount of Money for Retail Purchases of Chantix in the United States and Its Territories from September 29, 2015 through September 17, 2021, You May Be Entitled to a Payment from a Class Action Settlement.

A court authorized this notice. You are not being sued. This is not a solicitation from a lawyer.

- A Settlement has been reached in a putative class action lawsuit claiming that Pfizer Inc. (“Pfizer”) manufactured and sold its branded drug Chantix, which Plaintiffs alleged contained an undisclosed nitrosamine. Pfizer believes it did nothing wrong and denies violating any law but has agreed to the Settlement to avoid the uncertainties and expenses associated with continuing the case.
- You are included if you paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021. Third Party Payors included in the Settlement will be eligible to receive a *pro rata* portion of the Settlement Fund, which will be based on the total amount of qualifying and documented payments.
- Read this notice carefully. Your legal rights are affected whether you act, or do not act.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A CLAIM FORM BY SEPTEMBER 14, 2026	This is the only way to receive a payment.
EXCLUDE YOURSELF BY SEPTEMBER 14, 2026	You will receive no benefits, but you will retain any rights you currently have to sue Pfizer about the claims in this case.
OBJECT BY SEPTEMBER 14, 2026	Write to the Court explaining why you do not like the Settlement.
GO TO THE HEARING ON OCTOBER 13, 2026	Ask to speak in Court about your opinion of the Settlement.
DO NOTHING	You will not receive a share of the Settlement benefits and will give up your rights to sue Pfizer about the claims in the case.

These rights and options—**and the deadlines to exercise them**—are explained in this Notice.

BASIC INFORMATION

1. Why was this Notice issued?

A Court authorized this notice because you have a right to know about a proposed Settlement of this putative class action lawsuit and about all of your options, before the Court decides whether to give final approval to the Settlement. This Notice explains the lawsuit, the Settlement, and your legal rights.

The Honorable Katherine Polk Failla, of the U.S. District Court for the Southern District of New York, is overseeing this case. The case is called *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.). The people who sued are called the Plaintiffs. The Defendant is Pfizer.

2. What is a class action?

In a putative class action, one or more people called plaintiffs or class representatives (in this case, Juan Abreu, Teresa Baptiste, Timothy Bleeker, Harold Bradley, Sharon Carroll, Karen Duff, Albert Edwards, Tara Evans, Lillian Forrest, Kimberly Hill, Valerie Hogue, Douglas Houghton, James Jacobson, Tammy LaMotte, Kathleen Lima, Deborah Seeley, Daniel Spence, Hazel Taylor, Carita Thompson, Daphne Walter, and Shannon Webb a/k/a Shannon Alicea (the “Consumer Plaintiffs”) and County of Monmouth, MSP Recovery Claims Series 44, LLC, MSP Recovery Claims, Series LLC, and Ohio Carpenters’ Health Fund (“TPP Plaintiffs”)) sue on behalf of a group or a “class” of people who have similar claims. If the court determines the case can proceed as a class action, the court resolves the issues for all class members, except for those who exclude themselves from the class.

3. What is this lawsuit about?

Plaintiffs alleged that Pfizer failed to comply with current good manufacturing practices, which resulted in Chantix becoming contaminated with a nitrosamine and asserted claims for: (1) breach of express warranties; (2) breach of implied warranties; (3) violation of the Magnuson-Moss Warranty Act, 15 U.S.C. § 2301 *et seq.*; (4) fraud (affirmative misrepresentation, omission, and concealment); (5) negligent misrepresentation and omission; (6) violation of state consumer protection laws; (7) negligence; (8) negligence per se; and (9) unjust enrichment. The Court issued prior orders that limited the claims to Plaintiffs’ consumer protection claims and certain unjust enrichment and negligent misrepresentation claims to proceed based on the “cGMP Misstatement, *i.e.*, that Pfizer misrepresented its adherence to current Good Manufacturing practices in its manufacturing of Chantix.” Pfizer believes it did nothing wrong and denies violating any law. The Court has not determined who is right. Rather, the Parties have agreed to settle the lawsuit to avoid the uncertainties and expenses associated with ongoing litigation.

4. Why is there a Settlement?

The Court has not decided whether the Plaintiffs or Pfizer should win this case. Instead, both sides agreed to this Settlement. That way, they avoid the uncertainties and expenses associated with ongoing litigation, and Settlement Class Members are guaranteed to receive compensation, and sooner rather than, if at all, after the completion of a trial.

WHO'S INCLUDED IN THE SETTLEMENT?

5. How do I know if I am in the Settlement Class?

The Court decided that everyone who fits the following description is a member of the **Settlement Class**:

All individuals and third-party payors who paid any amount of money for retail purchases of Chantix in the United States and its territories from September 29, 2015 through September 17, 2021.

The following groups have been excluded from the Settlement Class in this case:

- a. Pfizer and its officers, directors, managers, employees, subsidiaries, and affiliates;
- b. Government agencies or governmental actors, including, without limitation, any state Attorney General office; and
- c. Any entity that previously opted out of the Settlement Class in this Action.

THE SETTLEMENT BENEFITS

6. What does the Settlement provide?

In consideration of the full and complete release of all Released Claims against Pfizer, and the dismissal of the lawsuit with prejudice, Pfizer agrees to provide the following consideration to the Settlement Class: Pfizer will pay \$44,000,000.00.

The net Settlement Fund available for distribution to the Settlement Class, after deduction of any attorneys' fees, litigation expenses, settlement administration and notice expenses, and class representative service awards that may be ordered by the Court, shall be first allocated between consumers (described in a separate notice to the Consumer Settlement Class) up to a maximum of 20% of the Available Settlement Fund, with the remainder allocated to third-party payors ("TPPs"); allocation to Third-Party Settlement Class Members will be as follows:

For Third-Party Payors: After a determination of the total fund to be allocated to Third-Party Payors, each Third-Party Payor class member that submits an eligible claim will receive a *pro-rata* share of the funds based on dollars paid as documented in claim forms and supporting documents submitted.

A detailed description of the Settlement benefits can be found in the Settlement Agreement, a copy of which is accessible on the Settlement Website by clicking [here](#).

7. How will my payment be determined?

Third-Party Payor Settlement Class Members (including assignees of TPPs) shall submit Claim Forms documenting their (or their assignors') payments for Pfizer as provided in the Settlement Agreement and approved by the Court. The Settlement Administrator will review the Claim Forms and any supporting documentation with particular attention to the possibility of fraudulent or mistaken claims. After payment of the consumer claims as provided above, the remainder of the Settlement Fund shall be distributed to each valid Third-Party Payor Settlement Class Member (including assignees) on a *pro rata* basis according to the total amount of each TPP's qualifying and documented payments.

If you are an eligible Settlement Class Member, you must submit a Claim Form to receive a Settlement payment. You can submit your Claim Form online at the Settlement Website, www.ChantixSettlement.com, or download a paper Claim Form from the Settlement Website and submit it by mail. You will be required to submit supporting documentation. Assignees of third-party payors may directly submit claims to obtain settlement funds. Such assignees will be treated as if the third-party payor had directly submitted its claims as part of the claims administration process, and it will have the same rights as a third-party payor. Settlement Class Members are limited to one claim per Settlement Class Member. Related companies, such as corporate subsidiaries or affiliates, may file claims either separately or combined. In no event shall more than one Settlement Class Member assert a claim for the same payments. Your Claim Form must be submitted online or postmarked by **September 14, 2026**.

8. When will I get my payment?

The hearing to consider the fairness of the Settlement is scheduled for **October 13, 2026 at 3 p.m.** Please note that the fairness hearing date is subject to change without further notice. If the Court approves the Settlement, there may be appeals. It is always uncertain when appeals will be resolved, and even if no appeals are filed, it also takes time for the Settlement Administrator to process all claims and make payments. Please be patient.

HOW TO GET BENEFITS

9. How do I get a payment?

Third-Party Payor Settlement Class Member (including assignees of TPPs) shall submit Claim Forms documenting their (or their assignors') payments for Chantix as provided in the Settlement Agreement and approved by the Court. The Settlement Administrator will review the Claim Forms and any supporting documentation with particular attention to the possibility of fraudulent or mistaken claims. After payment of the consumer claims as provided above, the remainder of the Settlement Fund shall be distributed to each valid Third-Party Payor Settlement Class Member (including assignees) on a *pro rata* basis according to the total amount of each TPP's qualifying and documented payments.

If you are an eligible Settlement Class Member, you must submit a Claim Form to receive a Settlement payment. You can submit your Claim Form online at the Settlement Website by **September 14, 2026** or download a paper Claim Form from the Settlement Website and submit it by mail. You will be required to submit supporting documentation. Settlement Class

Members are limited to one claim per Settlement Class Member. A Third-Party Payor Settlement Class Member or an authorized agent can complete this Claim Form. If both a Settlement Class Member and its authorized agent submit a Claim Form, the Settlement Administrator will only consider the Settlement Class Member's Claim Form. The Settlement Administrator may request supporting documentation. The claim may be rejected if any requested documentation is not provided in a timely manner. In no event shall more than one Settlement Class Member assert a claim for the same payments. Your Claim Form must be submitted online or postmarked by **September 14, 2026**.

REMAINING IN THE SETTLEMENT

10. What am I giving up if I stay in the Settlement Class?

If the Settlement becomes final, you will give up your right to sue Pfizer and other Released Parties for the claims being resolved by this Settlement. The specific claims you are giving up against Pfizer are described in the Settlement Agreement. You will be “releasing” Pfizer and certain of its subsidiaries, affiliates, employees, and representatives as described in Section 3 of the Settlement Agreement. Unless you exclude yourself (*see* Question 13), you are “releasing” the claims, regardless of whether you claim your payment or not. The Settlement Agreement is available through the “Court Documents” link on the Settlement Website.

The Settlement Agreement describes the released claims with specific descriptions, so read it carefully. If you have any questions, you can talk to the lawyers listed in Question 11 for free or you can, of course, talk to your own lawyer if you have questions about what this means.

THE LAWYERS REPRESENTING YOU

11. Do I have a lawyer in the case?

Yes, if you do not exclude yourself from the Settlement Class by opting out. The Court has appointed Ruben Honik and David J. Stanoch of Honik LLC, Charles E. Schaffer of Levin Sedran & Berman LLP, and Joseph P. Guglielmo of Scott+Scott Attorneys at Law LLP to be the attorneys representing the Settlement Class. They are called “Class Counsel.” They believe, after conducting an extensive investigation, that the Settlement Agreement is fair, reasonable, and in the best interests of the Settlement Class. You will not be charged for these lawyers. If you want to be represented by your own lawyer in this case, you may hire one at your expense.

12. How will the lawyers be paid?

Class Counsel will petition for attorneys' fees and costs that may be paid out of the Settlement Fund in an amount to be determined by the Court. The fee petition will seek no more than one-third of the Settlement Fund, plus reimbursement of their costs and expenses.

Under the Settlement Agreement, any amount awarded to Class Counsel will be paid out of the Settlement Fund.

Subject to approval by the Court, Plaintiff intends to seek service awards for the Class Representatives from the Settlement Fund in the amount of \$15,000 each for TPP Plaintiffs and \$5,000 each for Consumer Plaintiffs for their services in helping to bring and resolve this case.

EXCLUDING YOURSELF FROM THE SETTLEMENT

13. How do I get out of the Settlement?

To exclude yourself from the Settlement, you must submit a request for exclusion by **11:59 P.M. EST on September 14, 2026**. Requests for exclusion may be submitted either on the Settlement Website (via the online form accessible [here](#)) or by mailing or otherwise deliver a letter (or request for exclusion) stating that you want to be excluded from the *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.) Settlement. Your letter or request for exclusion must also include your full name and current address, a statement that you purchased Chantix in the United States and its territories between September 29, 2015 through September 17, 2021, your signature, the name and number of this case, and a statement that you wish to be excluded. If you choose to submit a request for exclusion by mail, you must mail or deliver your exclusion request, postmarked no later than **September 14, 2026**, to the following address:

Chantix Settlement
c/o A.B. Data, Ltd.
P.O. Box 173137
Milwaukee, WI 53217

Any purported group, “mass,” or “class-wide” opt-outs shall not be permitted and shall be construed as being submitted only on behalf of the person who actually submitted the request for exclusion or objection. A request for exclusion must be submitted by each Settlement Class Member on an individual basis, and any request for exclusion by a purported authorized agent or representative of a Settlement Class Member must be signed by the Settlement Class Member and include proof of the representative’s legal authority and authorization to act and object to or request exclusion on behalf of each Settlement Class Member for which the representative requests exclusion.

14. If I do not exclude myself, can I sue Pfizer for the same thing later?

No. Unless you exclude yourself, you give up any right to sue Pfizer for the claims being resolved by this Settlement.

15. If I exclude myself, can I get anything from this Settlement?

No. If you exclude yourself, you will not receive any payment from the Settlement Fund.

OBJECTING TO THE SETTLEMENT

16. How do I object to the Settlement?

If you are a Settlement Class Member, you can object to the Settlement if you do not like any part of it. The deadline to object is **September 14, 2026**. You can give reasons why you think the Court should not approve it. The Court will consider your views. To object, you must file with the Court a letter or brief stating that you object to the Settlement in *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.) and identify all your reasons for your objections (including citations and supporting evidence) and attach any materials you rely on for your objections. Your letter or brief must also include your name, your address, the basis upon which you claim to be a Settlement Class Member, the name and contact information of any and all attorneys representing, advising, or in any way assisting you in connection with your objection, and your signature. If you, or an attorney assisting you with your objection, have ever objected to any class action settlement where you or the objecting attorney has asked for or received payment in exchange for dismissal of the objection (or any related appeal) without modification to the settlement, you must include a statement in your objection identifying each such case by full case caption. You must also mail or deliver a copy of your letter or brief to Class Counsel and Pfizer's Counsel listed below.

Objections must be filed via the Court's electronic filing system, and if not filed via the Court's electronic system, must be mailed, postmarked by **September 14, 2026**, to the Court at the following address:

Clerk of the Court
United States District Court
Southern District of New York
Thurgood Marshall
United States Courthouse
40 Foley Square
New York, NY 10007

If you want to appear and speak at the Final Approval Hearing to object to the Settlement, with or without a lawyer (explained below in Question 20), you must say so in your letter or brief. File the objection with the Court (or mail the objection to the Court) and mail a copy of the objection to Class Counsel and Pfizer's Counsel, at the addresses below, postmarked no later than **September 14, 2026**.

Class Counsel	Pfizer's Counsel
Ruben Honik Honik Law 1515 Market Street Suite 1100 Philadelphia, PA, 19102	Loren H. Brown DLA Piper LLP 1251 Avenue of the Americas, 27th Floor New York, NY 10020

17. What's the difference between objecting and excluding myself from the Settlement?

Objecting simply means telling the Court that you do not like something about the Settlement. If you object only, you will remain in the Settlement Class. Excluding yourself from the Settlement Class is telling the Court that you do not want to be part of the Settlement Class. If you exclude yourself, you have no basis to object because the case no longer affects you.

THE COURT'S FINAL APPROVAL HEARING

18. When and where will the Court decide whether to approve the Settlement?

The Court will hold the Final Approval Hearing on **October 13, 2026 at 3:00 p.m.** in Courtroom 618 of the United States District Court for the Southern District of New York, Thurgood Marshall United States Courthouse, 40 Foley Square, New York, NY 10007. The purpose of the hearing will be for the Court to determine whether to approve the Settlement as fair, reasonable, adequate, and in the best interests of the Settlement Class; consider Class Counsel's request for attorneys' fees and expenses; and consider the request for service awards to the Class Representatives. At that hearing, the Court will be available to hear any objections and arguments concerning the fairness of the Settlement.

The hearing may be postponed to a different date or time without notice, so it is a good idea to check for updates by visiting the Settlement Website at www.ChantixSettlement.com or calling 1-877-354-3912. If, however, you timely objected to the Settlement and advised the Court that you intend to appear and speak at the Final Approval Hearing, you will receive notice of any change in the date of the Final Approval Hearing.

19. Do I have to come to the hearing?

No. Class Counsel will answer any questions the Court may have. But, you are welcome to come at your own expense. If you send an objection or comment, you do not have to come to Court to talk about it. As long as you filed and mailed your written objection on time, the Court will consider it. You may also pay another lawyer to attend, but it's not required.

20. May I speak at the hearing?

Yes. You may ask the Court for permission to speak at the Final Approval Hearing. To do so, you must include in your letter or brief objecting to the Settlement a statement saying that it is your "Notice of Intent to Appear in *In re Chantix (Varenicline) Mktg., Sales Pracs. & Prods. Liab. Litig.* (No. II) 22-MD-3050 (KPF), 22-MC-3050 (S.D.N.Y.)." It must include your name, address, telephone number and signature, as well as the name and address of your lawyer, if one is appearing for you. Your objection and notice of intent to appear must be filed with the Court, postmarked no later than **September 14, 2026**, and sent to the addresses listed in Question 16.

GETTING MORE INFORMATION

21. Where do I get more information?

This Notice summarizes the Settlement. More details are in the Settlement Agreement. You can get a copy of the Settlement Agreement at www.ChantixSettlement.com. You may also write with questions to Chantix Settlement, c/o A.B. Data, Ltd., P.O. Box 173137, Milwaukee, WI 53217. You can call the Settlement Administrator at 1-877-354-3912 or Class Counsel at 212-223-6444, if you have any questions. Before doing so, however, please read this full Notice carefully. You may also find additional information elsewhere on the Settlement Website.